Clinical Trial Update: Study of Therapy With TransMID™ Compared to Best Standard of Care in Patients With Glioblastoma Multiforme [Phase 3]

View source ↗

Summary

Phase 3 trial of TransMID™ for glioblastoma multiforme has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma Multiforme

Drugs mentioned

• TransMID

Snippet

Sponsor: Xenova Biomedix | Conditions: Glioblastoma Multiforme | Phase 3 | Status: WITHDRAWN